Patheon has opened its new early phase development facility in Milton Park in Oxfordshire, UK. The 13,500-sq.-ft development facility has newly constructed formulation labs and a fully equipped analytical lab. The facility will focus on the early phase development of solid, semi-solid and oral liquid dosage forms, and includes GMP manufacturing areas for the production of clinical trial materials for Phase I/II trials. The company’s Quick To Clinic programs, which work to accelerate molecules to clinical trials while minimizing API requirements, will be supported at the site. The facility holds an Investigational Medical Product License from the MHRA (UK).
   
“The Milton Park facility was created to meet our customers’ growing demand for rapid early phase development capacity in a strategic location”, said Norman Barras vice-president, Pharmaceutical Development Services, Europe. “We believe that our Quick to Clinic(TM) approach will provide a valuable opportunity to shorten the development times of our customers’ projects.”
   
“Milton Park is one of many significant additions that we plan to make in our development service offerings”, added Wes Wheeler, chief executive officer. “We are constantly striving to understand our customers’ needs and then respond accordingly.”